• Stereotactic radiosurgery alone for patients with up to 10 brain metastases

    The role of stereotactic radiosurgery (SRS) for patients with multiple metastases remains uncertain.  A prospective observational study published in Lancet Oncologyevaluates the use of SRS without addition of whole brain irradiation on survival for 1194 patients (KPS>70) with 1-10 newly diagnosed brain metastases. Inclusion criteria included largest tumor <10cc and <3cm in diameter and cumulative tumor volume <15cc.  Rates of median overall survival for patients with solitary metastasis, 2-4 metastases, and 5-10 metastases were 13.9, 10.8, and 10.8 months respectively.  While study interpretation may be limited by mixed tumor types and systemic treatments, this study demonstrates non-inferiority of only using SRS treatment on survival for patients with 5-10 metastases compared to those with 2-4 metastases, and supports the use of SRS alone in patients with 5-10 cerebral metastases. The impact of number of metastases on quality of life and neuro-cognition of the treated patients remains unclear.


    Lancet Oncology

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy